Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Hopes Eprex Experience Will Influence Follow-On Biologics Regulatory Pathway

This article was originally published in The Pink Sheet Daily

Executive Summary

Johnson & Johnson is discussing its Eprex manufacturing complications in Europe with regulators working to develop a follow-on biologics pathway

You may also be interested in...



Analytical Test Series Would Allow Characterization Of Follow-On Biologics – GPhA

"No 'one' analytical method is currently capable of such comprehensive analysis," a Generic Pharmaceutical Association white paper states. Previously reported characterization problems were due to inappropriate or misinterpreted tests, GPhA maintains.

Analytical Test Series Would Allow Characterization Of Follow-On Biologics – GPhA

"No 'one' analytical method is currently capable of such comprehensive analysis," a Generic Pharmaceutical Association white paper states. Previously reported characterization problems were due to inappropriate or misinterpreted tests, GPhA maintains.

BIO Comments On Follow-On Biologics Will Include Manufacturing Anecdotes

FDA officials' questions to industry reps during public workshop focus on the level of studies that should be required for follow-on biologic applications, particularly in comparison to requirements for manufacturing process changes by innovators.

Topics

UsernamePublicRestriction

Register

PS060578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel